Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Catalyst Pharmaceuticals (CPRX) Other Gross PP&E Adjustments (2016 - 2026)

Catalyst Pharmaceuticals filings provide 16 years of Other Gross PP&E Adjustments readings, the most recent being -$30.0 million for Q1 2026.

  • On a quarterly basis, Other Gross PP&E Adjustments fell 2.88% to -$30.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$30.0 million, a 2.88% decrease, with the full-year FY2025 number at -$10.8 million, up 11.28% from a year prior.
  • Other Gross PP&E Adjustments hit -$30.0 million in Q1 2026 for Catalyst Pharmaceuticals, down from -$10.8 million in the prior quarter.
  • In the past five years, Other Gross PP&E Adjustments ranged from a high of -$1.4 million in Q1 2024 to a low of -$30.0 million in Q1 2026.
  • Median Other Gross PP&E Adjustments over the past 5 years was -$6.2 million (2023), compared with a mean of -$9.9 million.
  • Biggest five-year swings in Other Gross PP&E Adjustments: surged 39.09% in 2022 and later tumbled 1911.11% in 2025.
  • Catalyst Pharmaceuticals' Other Gross PP&E Adjustments stood at -$2.8 million in 2022, then crashed by 125.52% to -$6.2 million in 2023, then tumbled by 95.15% to -$12.2 million in 2024, then increased by 11.28% to -$10.8 million in 2025, then plummeted by 177.17% to -$30.0 million in 2026.
  • The last three reported values for Other Gross PP&E Adjustments were -$30.0 million (Q1 2026), -$10.8 million (Q4 2025), and -$10.3 million (Q3 2025) per Business Quant data.